Query

Active Filters

  • (-) PSI Laboratories = Center for Radiopharmaceutical Sciences CRS
Search Results 1 - 20 of 168

Pages

  • CSV Spreadsheet
  • Excel Spreadsheet
  • RSS Feed
Select Page
Combined application of albumin-binding [<sup>177</sup>Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics
Borgna, F., Deberle, L. M., Cohrs, S., Schibli, R., & Müller, C. (2020). Combined application of albumin-binding [177Lu]Lu-PSMA-ALB-56 and fast-cleared PSMA inhibitors: optimization of the pharmacokinetics. Molecular Pharmaceutics, 17(6), 2044-2053. https://doi.org/10.1021/acs.molpharmaceut.0c00199
Separation and recovery of exotic radiolanthanides from irradiated tantalum targets for half-life measurements
Chiera, N. M., Talip, Z., Fankhauser, A., & Schumann, D. (2020). Separation and recovery of exotic radiolanthanides from irradiated tantalum targets for half-life measurements. PLoS One, 15(7), e0235711 (19 pp.). https://doi.org/10.1371/journal.pone.0235711
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
Deberle, L. M., Benešová, M., Umbricht, C. A., Borgna, F., Büchler, M., Zhernosekov, K., Schibli, R., & Müller, C. (2020). Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Theranostics, 10(4), 1678-1693. https://doi.org/10.7150/thno.40482
The A/T/N model applied through imaging biomarkers in a memory clinic
Dodich, A., Mendes, A., Assal, F., Chicherio, C., Rakotomiaramanana, B., Andryszak, P., Festari, C., Ribaldi, F., Scheffler, M., Schibli, R., Schwarz, A. J., Zekry, D., Lövblad, K. O., Boccardi, M., Unschuld, P. G., Gold, G., Frisoni, G. B., & Garibotto, V. (2020). The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 47(2), 247-255. https://doi.org/10.1007/s00259-019-04536-9
Determination of <sup>161</sup>Tb half-life by three measurement methods
Durán, M. T., Juget, F., Nedjadi, Y., Bochud, F., Grundler, P. V., Gracheva, N., Müller, C., Talip, Z., van der Meulen, N. P., & Bailat, C. (2020). Determination of 161Tb half-life by three measurement methods. Applied Radiation and Isotopes, 159, 109085 (9 pp.). https://doi.org/10.1016/j.apradiso.2020.109085
Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes
Fonta, C. M., Arnoldini, S., Jaramillo, D., Moscaroli, A., Oxenius, A., Behe, M., & Vogel, V. (2020). Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes. Matrix Biology Plus, 100046. https://doi.org/10.1016/j.mbplus.2020.100046
Radiation dosimetry of <sup>18</sup>F-AzaFol: a first in-human use of a folate receptor PET tracer
Gnesin, S., Müller, J., Burger, I. A., Meisel, A., Siano, M., Früh, M., Choschzick, M., Müller, C., Schibli, R., Ametamey, S. M., Kaufmann, P. A., Treyer, V., Prior, J. O., & Schaefer, N. (2020). Radiation dosimetry of 18F-AzaFol: a first in-human use of a folate receptor PET tracer. EJNMMI Research, 10(1), 32 (12 pp.). https://doi.org/10.1186/s13550-020-00624-2
<sup>165</sup>Er: a new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets
Gracheva, N., Carzaniga, T. S., Schibli, R., Braccini, S., & van der Meulen, N. P. (2020). 165Er: a new candidate for Auger electron therapy and its possible cyclotron production from natural holmium targets. Applied Radiation and Isotopes, 159, 109079 (8 pp.). https://doi.org/10.1016/j.apradiso.2020.109079
Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions
Grob, N. M., Schmid, S., Schibli, R., Behe, M., & Mindt, T. L. (2020). Design of radiolabeled analogs of minigastrin by multiple amide-to-triazole substitutions. Journal of Medicinal Chemistry, 63(9), 4496-4505. https://doi.org/10.1021/acs.jmedchem.9b01937
Triazolo-peptidomimetics: novel radiolabeled minigastrin analogs for improved tumor targeting
Grob, N. M., Häussinger, D., Deupi, X., Schibli, R., Behe, M., & Mindt, T. L. (2020). Triazolo-peptidomimetics: novel radiolabeled minigastrin analogs for improved tumor targeting. Journal of Medicinal Chemistry, 63(9), 4484-4495. https://doi.org/10.1021/acs.jmedchem.9b01936
Biodistribution and dosimetry of a single dose of albumin-binding ligand [<sup>177</sup>Lu]Lu-PSMA-ALB-56 in patients with mCRPC
Kramer, V., Fernández, R., Lehnert, W., Jiménez-Franco, L. D., Soza-Ried, C., Eppard, E., Ceballos, M., Meckel, M., Benešová, M., Umbricht, C. A., Kluge, A., Schibli, R., Zhernosekov, K., Amaral, H., & Müller, C. (2020). Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-020-05022-3
First phantom-based quantitative assessment of scandium-44 using a commercial PET device
Lima, T. V. M., Gnesin, S., Nitzsche, E., Ortega, P. G., Müller, C., & van der Meulen, N. P. (2020). First phantom-based quantitative assessment of scandium-44 using a commercial PET device. Frontiers in Physics, 8, 241 (10 pp.). https://doi.org/10.3389/fphy.2020.00241
Biodistribution of site-specific PEGylated fibroblast growth factor-2
Lühmann, T., Gutmann, M., Moscaroli, A., Raschig, M., Béhé, M., & Meinel, L. (2020). Biodistribution of site-specific PEGylated fibroblast growth factor-2. ACS Biomaterials Science & Engineering, 6(1), 425-432. https://doi.org/10.1021/acsbiomaterials.9b01248
Establishment of a clinical SPECT/CT protocol for imaging of <sup>161</sup>Tb
Marin, I., Rydèn, T., Van Essen, M., Svensson, J., Gracheva, N., Köster, U., Zeevaart, J. R., van der Meulen, N. P., Müller, C., & Bernhardt, P. (2020). Establishment of a clinical SPECT/CT protocol for imaging of 161Tb. EJNMMI Physics, 7(1), 45 (16 pp.). https://doi.org/10.1186/s40658-020-00314-x
Measurement of the <sup>154</sup>Gd(n,<em>γ</em>) cross section and its astrophysical implications
Mazzone, A., Cristallo, S., Aberle, O., Alaerts, G., Alcayne, V., Amaducci, S., Andrzejewski, J., Audouin, L., Babiano-Suarez, V., Bacak, M., Dressler, R., Heinitz, S., Kivel, N., Maugeri, E., Rochman, D., Schumann, D., Talip, Z., Ulrich, J., & Žugec, P. (2020). Measurement of the 154Gd(n,γ) cross section and its astrophysical implications. Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics, 804, 135405 (6 pp.). https://doi.org/10.1016/j.physletb.2020.135405
Can nuclear imaging of activated macrophages with folic acid-based radiotracers serve as a prognostic means to identify COVID-19 patients at risk?
Müller, C., Schibli, R., & Maurer, B. (2020). Can nuclear imaging of activated macrophages with folic acid-based radiotracers serve as a prognostic means to identify COVID-19 patients at risk? Pharmaceuticals, 13(9), 238 (8 pp.). https://doi.org/10.3390/ph13090238
Expanding the scope of pyclen-picolinate lanthanide chelates to potential theranostic applications
Nizou, G., Favaretto, C., Borgna, F., Grundler, P. V., Saffon-Merceron, N., Platas-Iglesias, C., Fougère, O., Rousseaux, O., van der Meulen, N. P., Müller, C., Beyler, M., & Tripier, R. (2020). Expanding the scope of pyclen-picolinate lanthanide chelates to potential theranostic applications. Inorganic Chemistry, 59(16), 11736-11748. https://doi.org/10.1021/acs.inorgchem.0c01664
Strategic screening and characterization of the visual GPCR-mini-G protein signaling complex for successful crystallization
Pamula, F., Mühle, J., Blanc, A., Nehmé, R., Edwards, P. C., Tate, C. G., & Tsai, C. J. (2020). Strategic screening and characterization of the visual GPCR-mini-G protein signaling complex for successful crystallization. Journal of Visualized Experiments (157), e60747 (10 pp.). https://doi.org/10.3791/60747
Single photon emission computed tomography tracer
Pietzsch, H. J., Mamat, C., Müller, C., & Schibli, R. (2020). Single photon emission computed tomography tracer. In O. Schober, F. Kiessling, & J. Debus (Eds.), Recent results in cancer research: Vol. 216. Molecular imaging in oncology (pp. 227-282). https://doi.org/10.1007/978-3-030-42618-7_7
Cholecystokinin-2 receptor agonist <sup>177</sup>Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study
Rottenburger, C., Nicolas, G. P., McDougall, L., Kaul, F., Cachovan, M., Vija, A. H., Schibli, R., Geistlich, S., Schumann, A., Rau, T., Glatz, K., Behe, M., Christ, E. R., & Wild, D. (2020). Cholecystokinin-2 receptor agonist 177Lu-PP-F11N for radionuclide therapy of medullary thyroid carcinoma - results of the lumed phase 0a study. Journal of Nuclear Medicine, 61(4), 520-526. https://doi.org/10.2967/jnumed.119.233031
 

Pages